Inmedical
Our Story
2018
Covergel receives the award for the best research product of the M.I.T. Innovation Program. [View more]
2020
Inmedical Therapeutics was born, at the initiative of Antoni Villaró, after the acquisition of the global licensing rights.
2021
Luciano Conde and Fernando Martín Delgado joined.
2021
Subsequently, the three partners decided to incorporate i+Med S. Coop. into the capital of Inmedical.
2023
Contributions worth €2.0M from new investors.
2025
The product is currently undergoing clinical trials.
2029
Sales of one million units of Covergel are estimated.
Facilities
Where is Covergel manufactured?
Covergel is entirely manufactured at the state-of-the-art facilities of i+Med S. Coop, a cooperative of scientists and a European leader in the development and production of hydrogels and medical technologies, located in the Basque Country (Spain).
In addition to manufacturing, i+Med S. Coop also leads the technological development and clinical research of Covergel, including the execution of clinical trials — ensuring a fully integrated process from innovation to clinical validation.
This environment of scientific excellence allows us to guarantee a product of the highest quality, manufactured under strict standards and driven by a strong commitment to safety, innovation and regulatory compliance.
. The synergy between Inmedical Therapeutics’ clinical vision and i+Med’s technological, research, and manufacturing capabilities drives genuine and sustainable innovation.
Executive Team
Antoni Villaró Martín
President & CEO
Founder and strategic leader of Inmedical Therapeutics, Antoni has held senior executive roles in global pharmaceutical companies. He led Otsuka Pharmaceutical Europe as President & CEO and was a Board Member in Tokyo, driving the company’s transformation into a global leader. He also held key positions at Ferrer Internacional and Alexza Pharmaceuticals in California, and currently leads Adacyte Pharmaceuticals, focused on innovation in immune-mediated diseases and cancer prevention.
Luciano Conde Conde
Vice-President (Secretary)
Luciano is a founding partner of Inmedical Therapeutics and currently serves as Chief Business Officer at Ferrer Laboratories, pharmaceutical company specializing in neurology and pulmonary diseases. He has led operations and strategic growth at Roche, Pharmacia, Almirall, and Noventure, where he was CEO until its acquisition. As COO of Almirall, he oversaw global operations across 27 countries. He has also chaired the Board of NIM Genetics and served on multiple boards, contributing deep industry insight and leadership.
Fernando Martín-Delgado Santos
Chief Financial Officer (Vocal)
Fernando brings over four decades of leadership across the pharmaceutical and biotech industries. He is CEO of Mdsan Farmainvest, an investment and consulting company specializing in the pharmaceutical sector and serves as Board Member at PharmaMar. Throughout his career, he has held senior executive roles at leading global companies including GSK, MSD, Sanofi, Bristol-Myers Squibb, IQVIA, Syneos Health, and Almirall, where he led operations in Spain and Latin America. He also served as CEO of Genómica, a molecular diagnostics company within the PharmaMar Group.
Manuel Muñoz Morentín
Chief Operating Officer (Vocal)
Founder and Managing Director of i+Med S. Coop., the world’s first cooperative of scientists dedicated to the development and manufacturing of innovative technologies, biomedical devices and high value-added medicines. With over two decades of leadership in industrial and biomedical sectors, Manuel has directed i+Med’s growth from its inception into a global reference in nanohydrogel smart systems and controlled-release therapeutics, driving international expansion and major R&D investment. His career is defined by combining entrepreneurial vision with technological excellence and global market reach.
Jesús Izco, PhD
Scientific Advisor (Vocal)
As Corporate Diversification Manager at Viscofan, he leads initiatives to expand the company’s presence in biomedical and biotechnological markets, fostering partnerships and developing new collagen-based biomaterials. Before joining Viscofan, he held leadership positions at CIBER-BBN, where he coordinated research infrastructures and promoted collaboration between academia and industry in bioengineering and nanomedicine. His career reflects a strong commitment to innovation, technology transfer, and the translation of scientific advances into real-world industrial applications.
Investors
Jambo Healthcare S.L.
Lizaluc S.L.
MDSAN Farminvest S.L.
i+Med, S. Coop.
Viscofan España S.L.
Basque FCR > Gestión de Capital Riesgo del País Vasco S.A.
Interested in distributing Covergel?
Covergel is currently under clinical evaluation and not yet available for commercial distribution. We’re looking to connect with visionary partners who want to be part of its future launch once clinical validation and regulatory approval are achieved.